Previous 10 | Next 10 |
Mersana Therapeutics, Inc. (MRSN) Q1 2022 Earnings Conference Call May 09, 2022 08:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations and Corporate Communications Anna Protopapas - President, CEO & Director Arvin Yang - Senior VP & Chief Medical O...
Mersana Therapeutics press release (NASDAQ:MRSN): Q1 GAAP EPS of -$0.59 misses by $0.27. Revenue of $2.03M vs 0.01M prior year. Cash and cash equivalents as of March 31, 2022, were $230.1 million, compared to $177.9 million in cash and cash equivalents as of December 31, 2021 For further de...
Advanced UpRi development across UPLIFT, UPGRADE, and UP-NEXT clinical trials Prepared for expected initiation of patient dosing in Phase 1 clinical trials of XMT-1660 and XMT-2056 in mid-2022 Entered research collaboration and license agreement with Janssen, which provi...
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced...
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
XMT-1660 demonstrates robust activity in preclinical models of breast cancer XMT-2056 demonstrates robust activity as monotherapy, in combination with standard of care therapies and in both HER2-high and HER2-low expressing preclinical models Both programs on track to init...
Citing a recent data update, BTIG has issued a positive view on upifitamab rilsodotin (UpRi), the lead product candidate of clinical-stage biotech Mersana Therapeutics (NASDAQ:MRSN). At the ongoing Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Mersana (MRSN) was sch...
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announc...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...